These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36405580)

  • 1. Case report: Successful outcome of treatment using rituximab in an adult patient with refractory minimal change disease and β-thalassemia complicating autoimmune hemolytic anemia.
    Zhuang J; Zhao Z; Zhang C; Song X; Lu C; Tian X; Jiang H
    Front Med (Lausanne); 2022; 9():1059740. PubMed ID: 36405580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.
    Zhang J; Zhao H; Li X; Qian R; Gao P; Lu S; Ma Z
    BMC Nephrol; 2023 Apr; 24(1):112. PubMed ID: 37101300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of rituximab with or without glucocorticoid in inducing remission of MCD with different clinical presentations in adults: a retrospective study.
    Sun Y; Li Z; Sun J; Zhang S; Wang R; Chen B
    Clin Kidney J; 2024 Jun; 17(6):sfae139. PubMed ID: 38854425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome.
    Fenoglio R; Sciascia S; Beltrame G; Mesiano P; Ferro M; Quattrocchio G; Menegatti E; Roccatello D
    Oncotarget; 2018 Jun; 9(48):28799-28804. PubMed ID: 29989000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of rituximab in adult frequently relapsing minimal change disease.
    King C; Logan S; Smith SW; Hewins P
    Clin Kidney J; 2017 Feb; 10(1):16-19. PubMed ID: 28638601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.
    Papakrivopoulou E; Shendi AM; Salama AD; Khosravi M; Connolly JO; Trompeter R
    Nephrology (Carlton); 2016 Oct; 21(10):893-900. PubMed ID: 26860320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis.
    Ren H; Lin L; Shen P; Li X; Xie J; Pan X; Zhang W; Chen N
    Oncotarget; 2017 Nov; 8(55):93438-93443. PubMed ID: 29212162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment with rituximab of an infant with refractory autoimmune hemolytic anemia.
    Moriya K; Matsuhashi T; Onuma M; Niizuma H; Rikiishi T; Asada H; Suzuki J; Sasahara Y; Kure S
    Int J Hematol; 2013 Aug; 98(2):237-9. PubMed ID: 23702915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: Effective treatment of rituximab-resistant minimal change disease with obinutuzumab in an adult.
    Wang Q; Lin L; Zhen J; Jiang B; Liu G
    Front Immunol; 2024; 15():1407461. PubMed ID: 39136030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
    Kronbichler A; König P; Busch M; Wolf G; Mayer G; Rudnicki M
    Wien Klin Wochenschr; 2013 Jun; 125(11-12):328-33. PubMed ID: 23624956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.
    Niu XL; Hao S; Wang P; Zhang W; Guo GM; Wu Y; Kuang XY; Zhu GH; Huang WY
    Biomed Rep; 2016 Aug; 5(2):237-242. PubMed ID: 27446549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resolution of alloimmunization and refractory autoimmune hemolytic anemia in a multi-transfused beta-thalassemia major patient.
    Philip J; Jain N
    Asian J Transfus Sci; 2014 Jul; 8(2):128-30. PubMed ID: 25161355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
    Hansrivijit P; Cheungpasitporn W; Thongprayoon C; Ghahramani N
    BMC Nephrol; 2020 Apr; 21(1):134. PubMed ID: 32293308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The long-term efficacy and safety of rituximab combined with cyclophosphamide in treatment of seven patients with refractory and recurrent autoimmune hemolytic anemia].
    Liu H; Xing LM; Wang HQ; Wu YH; Qu W; Liang Y; Wang GJ; Song J; Wang XM; Guan J; Li LJ; Fu R; Shao ZH
    Zhonghua Nei Ke Za Zhi; 2012 Jun; 51(6):456-9. PubMed ID: 22943757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.
    Kisner T; Burst V; Teschner S; Benzing T; Kurschat CE
    Nephron Clin Pract; 2012; 120(2):c79-85. PubMed ID: 22286071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in adult patients with immunosuppressive-dependent minimal change disease.
    Hoxha E; Stahl RA; Harendza S
    Clin Nephrol; 2011 Aug; 76(2):151-8. PubMed ID: 21762648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive management of refractory autoimmune hemolytic anemia in pediatric beta-thalassemia major patient: A case report.
    William V; Rusmawatiningtyas D; Makrufardi F; Widjajanto PH
    Ann Med Surg (Lond); 2021 Oct; 70():102853. PubMed ID: 34691416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai.
    Sun L; Xu H; Shen Q; Cao Q; Rao J; Liu HM; Fang XY; Zhou LJ
    World J Pediatr; 2014 Feb; 10(1):59-63. PubMed ID: 24464665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Rituximab and Its Biosimilar in Treating Adult Steroid-Dependent Minimal Change Disease and Relapse.
    Shan HY
    Cureus; 2023 Nov; 15(11):e49200. PubMed ID: 38130516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.